Skip Navigation


JAC Advance Access originally published online on September 20, 2002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
50/4/611    most recent
dkf175v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Caniça, M.
Right arrow Articles by the Multicentre Study Group,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Caniça, M.
Right arrow Articles by the Multicentre Study Group,
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2002) 50, 611-612
© 2002 The British Society for Antimicrobial Chemotherapy

Correspondence

In vitro activity of extended-spectrum cephalosporins against Streptococcus pneumoniae strains with reduced susceptibility to penicillin isolated from patients in Portugal between 1995 and 2000

Manuela Caniça*, Ricardo Dias, Deolinda Louro, Catarina Carvalho and the Multicentre Study Group§

Antibiotic Resistance Unit, National Institute of Health Dr Ricardo Jorge, Av. Padre Cruz, 1649-016 Lisboa, Portugal

The first 10% of the full text of this article appears below.

Sir,

The prevalence of serious infections (meningitis, pneumonia, respiratory tract infections) caused by strains of pneumococci with reduced susceptibility to penicillin is increasing throughout the world.1 Thus, the third-generation cephalosporins cefotaxime and ceftriaxone have become important drugs in the treatment of pneumococcal infections, particularly in cases of meningitis. However, pneumococcal strains exhibiting high levels of resistance to these ß-lactams have been described,2–4 often associated with therapeutic failure. Furthermore, strains with diminished susceptibility . . . [Full Text of this Article]

Acknowledgements


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. A. Karlowsky and M. E. Jones
Importance of using current NCCLS breakpoints to interpret cefotaxime and ceftriaxone MICs for Streptococcus pneumoniae
J. Antimicrob. Chemother., February 1, 2003; 51(2): 467 - 468.
[Full Text] [PDF]